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requirement the demonstration that a clonogenic cell isEric Lagasse,*§ Judith A. Shizuru,†
Nobuko Uchida,* Ann Tsukamoto,* capable of self-renewal and differentiation to the ex-
pected daughter cells in that tissue. Hematopoietic stemand Irving L. Weissman‡
*StemCells cells (HSC) are therefore clonogenic cells, which make
more HSC, as well as all oligolineage progenitors and525 Del Rey Avenue, Suite C
Sunnyvale, California 94085 differentiated progeny. The isolation of stem cells has
required, therefore, quantitative assays for clonogenic†Division of Bone Marrow Transplantation
‡Department of Pathology and Developmental Biology cells with readouts for both self-renewal and differenti-
ation.Stanford University School of Medicine
Stanford, California 94305 Four general assumptions based on HSC underlie the
translation of stem cell biology to regeneration medi-
cine, and form the basis for this review. They are: (1)Much of medicine practiced today involves the use
tissue-specific stem cells exist for each hematopoieticof small molecules to intervene in a disease process;
and nonhematopoietic organ or tissue tested; (2) HSCfollowing elimination of the lesion, we expect the body to
can be isolated prospectively and can replace whole BMregenerate lost cells and functions. While small molecule
(or mobilized peripheral blood [MPB]) in hematopoieticmedicine has the advantage of the specificity of the
transplants; (3) allogeneic HSC transplantation is feasi-molecule for the proposed target, usually protein, the
ble in myeloablated and nonmyeloablated hosts andtargeted and related proteins with the same or similar
results in permanent chimeras that have specific trans-binding sites are usually present not only in the target
plantation tolerance to donor histocompatibility anti-cells but also in most other cells in the body. Therefore,
gens without graft versus host disease or continuedwith the exception of drugs designed for infectious
immunosuppression; and (4) transplantation of HSCagents, most small molecule medicine has attendant
from nonautoimmune donors into MHC-determined au-toxicities at high doses. Thus, cells could be lost both
toimmune hosts (such as type I diabetes-prone NODas a result of the disease process and drug toxicities.
mice) can permanently abrogate the autoimmune state.When the body begins the healing process, it is un-
We will present a compilation of experiments in thisclear as to which cells are in fact involved in regenera-
review that support all four assumptions.tion. The study of regeneration of the hematopoietic
system, driven by the need for bone marrow transplanta-
tion, revealed that the blood forming system is made up Mouse Hematopoietic Stem Cells
At least three subsets of clonogenic multipotent cellsof stem and progenitor cells as well as more committed
progeny. With the isolation of purified mouse hemato- dedicated to the hematopoietic lineage have been pro-
spectively isolated by their distinct array of cell surfacepoietic stem cells (HSC) (reviewed in Weissman, 2000),
it became possible to compare stem cells with all other markers (Morrison and Weissman, 1994) (Figure 1). In
our laboratory, they are c-kit1 (K) Thy-1.1lo (T) Lin2/lo (L)bone marrow (BM) cells in the regenerative process.
Surprisingly, in the context of transplantation, only HSC Sca-11 (S) cells. At the single cell level, these cells show
.80% efficiency for hematopoietic multilineage differ-and not other BM cells, such as progenitors, were impor-
tant for both short-term engraftment and sustained re- entiation. KTLS cells can be prospectively separated
into three distinct subsets that make up a lineage: long-generation. This is likely due in part to preferential hom-
ing of HSC versus other BM cells to hematopoietic term HSC (LT-HSC) ! short-term HSC (ST-HSC) !
multipotent progenitor (MPP). LT-HSC self-renew per-niches, but for the most part is due to the fact that in
hematopoiesis only HSC self-renew. Thus, self-renewal petually, ST-HSC self-renew for 6–8 weeks, and self-
renewal of MPP has been difficult to demonstrate. LT-seems to be the key for tissue regeneration in the hema-
topoietic system. As we wish to extend the principles HSC represent z.007%, ST-HSC z.01%, and MPP
z.03% of young adult C57BL mouse BM. The populationof stem cell biology and cell transplantation to areas
beyond the hematopoietic system, that is to tissue and of clonogenic KTLS cells represents only 1/2,000 cells
in the bone marrow and is 2000-fold enriched in theorgan regeneration, we need to test in each system
whether the stem/progenitor/progeny cell model holds radioprotection capacity to CD45 congenic hosts, re-
sulting in life-long donor-derived hematopoiesis. Thus,for that tissue, whether the stem and progenitor cells
are used only in embryonic development or if the stem only 100 HSC are required to save .95% of the mice,
the minimum radioprotective dose, and 20–30 cells areand progenitor cells remain for adult regeneration, and
whether the stem and progenitor cells can be prospec- required to save 50% of the mice. The homing efficiency
of KTLS cells to the bone marrow is between 5%–10%.tively isolated.
Stem cells have been defined as clonogenic cells that Thus, of 100 cells, only 5%–10% home to marrow, and
only 1–2 LT-HSC are likely to have engrafted (Smith etundergo both self-renewal and differentiation to more
committed progenitors and functionally specialized ma- al., 1991). As one increases the dose of marked donor
HSC, one increases the number of clones that partici-ture cells (Till and McCulloch, 1961). Thus, any claim for
isolation or identification of stem cells has as a minimal pate in life-long engraftment (Klug et al., 2000). LT-HSC
enter cell cycle randomly at a rate of about 8% of the
population per day (Cheshier et al., 1999), consistent§ E-mail: elagasse@stemcell.net.
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Figure 1. Model of Hematopoietic Stem Cell Differentiation
Long-term hematopoietic stem cells (LT-HSCs, c-kit1Thy1.1loLinnegSca11) are highly self-renewing cells that ultimately will give rise to all
mature blood cells. The process of HSC differentiation involves the loss of self-renewal with functionally irreversible maturation steps.
with the notion that all HSC participate in hematopoiesis. ers of committed myeloerythroid and lymphocyte lin-
When one compares the radioprotective and en- eages. Like mouse HSC, human HSC are Thy-1 positive
graftment capacity of the KTLS population (LT-HSC, ST- (Baum et al., 1992). CD34 was the first marker found on
HSC, and MPP) with the amount of bone marrow that human hematopoietic progenitors (Civin et al., 1984)
contains these KTLS cells plus all of the oligolineage and, along with the Thy1, Lin2 cocktail, marks human
progenitors and maturing hematolymphoid cells, it is HSC (Baum et al., 1992; Craig et al., 1993). CD34 could
clear that hematopoietic engraftment of at least periph- be substituted by the HCC-1 antibody to a CD59 family
eral blood red blood cells, platelets, and white blood member (Hill et al., 1996) (in mouse the Sca-1 antibody
cells is entirely dependent on the content of HSC, with also detects a CD59 family member). Recently, CD133
little or no contribution from all of the other hematopoi- has been identified as yet another marker that might
etic progenitors and progeny (Uchida et al., 1994). In substitute for CD34 (Yin et al., 1997). Both mouse and
mouse as in human, HSC can be mobilized into the human HSC also express the c-kit receptor tyrosine
bloodstream by treating the host with cytoxan plus kinase. The CD341Thy1Lin2 (c-kitlo) phenotype identifies
G-CSF. In the early phase of this treatment, HSC expand human HSC in adult BM, adult MPB, fetal liver, fetal
dramatically in BM, prior to their exit to contribute to BM, and umbilical cord blood (Tsukamoto et al., 1995).
mobilized peripheral blood (MPB), which is a complex Human HSC reconstitute irradiated SCID-Hu and NOD-
mixture of cells. Even the rapid reconstitution that has SCID mice efficiently. It is important to point out that
been achieved in clinical practice can be attributed to the CD341 BM population represents 1%–6% of bone
HSC in the mouse model. For example, 100 KTLS cells marrow, while the HSC subset represents only about
engraft white blood cells (WBC), red blood cells (RBC),
.05%; thus, the CD341 population includes, in addi-
and platelets at 20–28 days, while 1000 KTLS cells en-
tion to HSC, non-HSC cells. The CD341382 popula-graft by day 15, and 5000 KTLS HSC gave engraftment
tion overlaps significantly but not completely withtimes of 9–11 days. This is true whether mobilized or
CD341Thy1Lin2 cells; the most stringent isolation ofbone marrow KTLS HSC are transplanted and whether
resting LT-HSC is CD341Thy1Lin2CD382 (Uchida etonly primitive LT-HSC or all HSC subsets are used
al., 1998). In MPB, 5%–50% of CD341 cells are Thy-11(Uchida et al., 1998). As described below, allogeneic
(Murray et al., 1995). Prospectively isolated MPBtransplantation of HSC follows related dose-response
CD341Thy1Lin2 HSC from patients with widely meta-kinetics. These experiments provided the necessary
static breast cancer, non-Hodgkin’s lymphoma (NHL),preclinical methods and models to pursue human HSC
and multiple myeloma (MM) are nearly or completelyisolation and transplantation.
purged of contaminating cancer cells, whereas using
CD34 only isolation results in variable retention of cancerProspective Isolation and Transplantation of Purified
cells (see below) (Negrin et al., 2000). Similarly, prospec-Human Hematopoietic Stem Cells
tively isolated human HSC are largely if not completelyUsing similar clonogenic assays, candidate human HSC
were isolated. Like mouse HSC, human HSC lack mark- purged of T cells, a fact that will be important in consid-
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called them “HSC transplants,” an unfortunate semantic
error as their MPB included HSC, CK1 cells, and a pleth-
ora of other blood cells. Similarly, isolation of MPB or
CD341 cells from myeloma patient MPB failed to purge
the population of myeloma cells, whereas in most if not
all patients the CD341Thy1 MPB HSC population is free
of detectable myeloma cells (Michallet et al., 2000). The
data are similar in the non-Hodgkins lymphoma popula-
tion (J. Vose, personal communication). We therefore
conclude that human MPB CD341Thy1 HSC can be iso-
lated in numbers sufficient for rapid engraftment and
that these HSC are purged of contaminating breast can-
cer cells, NHL cells, and MM, as well as T cells.
Hematopoietic Progenitor Cells
Isolation of oligolineage hematopoietic progenitors fol-
lowed the approach used to isolate HSC. Because IL-7
signaling via the IL-7 receptor is a nonredundant require-
ment for lymphocyte development, the search for com-Figure 2. Cumulative Data on Patients with Metastatic Breast Can-
mon lymphocyte progenitors (CLP) began by testing thecer Transplanted with Purified HSC (CD341Thy-11)
IL-7 receptor (R)-defined subset of BM cells enrichedShown are the times of engraftment of neutrophils (absolute neutro-
for lymphoid progenitor activity. Testing other markers,phil count [ANC]) and platelets (PLT) following HSC transplant.
clonal CLP were purified to homogeneity (Kondo et al.,
1997). Because myeloerythroid progenitors are likely to
be c-kit1, BM nonlymphoid progenitors were soughterations of allotransplantation of HSC with the intent to
preclude graft versus host disease (GVHD), discussed among the IL-7R negative, c-kit1 population. Three ma-
jor classes of myeloid progenitors were isolated, thebelow.
About 100 patients with stage IV metastatic breast clonal common myeloid progenitor (CMP) (CD341FcgRlo),
and its downstream more restricted progenitor sub-cancer (Negrin et al., 2000), or NHL (J. Vose, personal
communication), or multiple myeloma (Tricot et al., 1998; sets—the megakarocyte/erythrocyte progenitor (MEP)
(CD342FcgRlo) and the granulocyte/monocyte progenitorMichallet et al., 2000) have now been transplanted with
purified CD341Thy1 autologous MPB HSC as a rescue (GMP) (FcgRhiCD341) (Figure 1) (Akashi et al., 2000). Each
of these progenitors responds as single cells with 65%–protocol following otherwise lethal myeloablation che-
motherapy. In all patient groups, the minimum dose to 98% efficiency in vitro to colony-forming assays. The
hematopoietic lineage presented in Figure 1 representsachieve rapid engraftment of .500 ANC (absolute neu-
trophil count) is 2–4 3 105 CD341Thy1 HSC per kg, while direct analysis of cell differentiation outcomes. These
purified stem and progenitor populations have beenthe dose to achieve rapid platelet engraftment (.20,000
per ml) is 8 3 105 CD341Thy1 HSC per kg (Figure 2). It used to identify genes selectively expressed at each of
these stages of differentiation; in an interesting experi-is interesting to note that the minimum dose of mouse
HSC required to achieve rapid engraftment of both ment, it has been possible to transfect a CMP/GMP
gene to convert CLP to the GMP lineage (Kondo et al.,platelets and white blood cells in the congenic setting
is 5000 cells, which translates to z2 3 105 per kg (Uchida 2000).
CLP are about the same frequency as HSC in mouseet al., 1998). In the breast cancer trial, 35% of the MPB
had cytokeratin positive (CK1) presumptive breast can- resting bone marrow (.01%–.05%); mice transplanted
with equal numbers of CD45 congenic HSC and CLPcer cells, and the first step isolation of CD341 cells did
not purge all samples of CK1 cells, whereas in all 22 show more rapid appearance of T, B, and NK cells from
the CLP than from HSC. In these experiments, the peaktransplanted samples no detectable CK1 cells were
found in the CD341Thy1 inoculum (Negrin et al., 2000). number of lymphoid progeny derived from CLP or HSC
is approximately equivalent (Kondo et al., 1997). Thus,The fraction of these transplanted patients who were
free of disease progression (FFP) from 18 months to at transplanted CLP could provide lymphoid cells earlier
than HSC. Mice transplanted with CLP 1 HSC can pre-least 32 months was 41%. No prospectively randomized
patient group with either conventional chemotherapy or vent a lethal dose of mouse cytomegalovirus (CMV) in-
fection in a setting where HSC transplanted hosts allunpurified autologous MPB transplants was included in
this phase I/II study. A contemporaneous study compar- died (J. W. Brown, unpublished data). CMV is one of
the pathogens that appears often and can be lethal ining conventional chemotherapy with unpurified MPB
rescue of similarly myeloablated stage IV cancer pa- transplant patients and immunodeficient patients. We
wished to test whether any of the other progenitorstients gave FFP percentages that were not different from
each other, but only 6% of the MPB patient group had could ameliorate other pathogenic infections. Aspergil-
lus fumigatus is a fungal infection that, in the transplantFFP at 32 months (Stadtmauer et al., 2000). Previously,
this group had published that on the order of 35%–50% setting, is almost universally lethal. The conidial form of
Aspergillus taken from a BMT patient is lethal when 100of their stage IV breast cancer MPB samples were con-
taminated with CK1 cells. It would seem reasonable conidia were injected into the bloodstream of 950cGy
irradiated, HSC transplanted mice (J. W. Brown, unpub-next to carry out a head-to-head trial. The study by
Stadtmauer et al. transplanted unpurified MPB cells, yet lished data). Cotransplantation of CMP, GMP, and HSC
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allowed full protection; if the conidia were injected very result in higher incidences of engraftment failure and
loss of GVT activity.early after transplant, the addition resulted in a signifi-
The problem of engraftment failure of HSC can becant fraction that survived. It is important to note that
approached by altering the recipient conditioning regi-none of these doses of CMP/GMP give rise to donor-
mens and/or by manipulating the HSC graft. The generalderived neutrophils above background in the blood; but
practice of allogeneic HCT is to prepare recipients toabundant development of neutrophils and monocytes/
accept the hematopoietic graft with myeloablative regi-macrophage lineage cells had occurred in tissue such
mens that are also effectively lymphoablative. In experi-as spleen and bone marrow (J. W. Brown, unpublished
mental animals, such preparation is delivered in the formdata). In early trials of HSC 1 CMP 1 GMP in a fully
of radiation. Resistance to allogeneic hematopoietic cellallogeneic setting, Aspergillus-induced host death can
engraftment occurs despite lethal radiation. From thebe prevented (J. W. Brown, unpublished data).
studies of Cudkowicz (Cudkowicz and Bennett, 1971)In the setting of transplantation, it is important also
and later by Kumar and Bennett (Bennett, 1987), it wasto achieve the development of antigen-presenting den-
determined that resistance to engraftment of hemato-dritic cells (DC). Recently, two classes of DC have
poietic cells differs from conventional solid organ trans-emerged in mouse and human: CD81, so-called lym-
plants with regard to both the genetics of resistancephoid DC cells, and CD82, so-called myeloid DC (Wu
and the cell populations that mediate resistance to en-et al., 1998). We compared CLP and CMP in the genera-
graftment. Rejection of conventional organ grafts is me-tion of these DC subpopulations in a transplantation
diated by T lymphocytes, and since F1 mice codomi-setting and found, to our surprise, that both CMP and
nantly express the restricting parental MHC molecules,CLP can give rise to both CD81 and CD82 DC in the
they accept organ grafts from either parental strain with-spleen and CD1 DC in the thymus (Traver et al., 2000).
out immune suppression. In contrast, F1 offspring canGiven that CMP are present at 10-fold the abundance
vigorously resist parental hematopoietic cells, even fol-of CLP, we concluded that not only are CD81 DC not
lowing myeloablative lethal irradiation (Cudkowicz andlymphoid dendritic cells, but for 90% of them the most
Bennett, 1971; Bennett, 1987). This phenomenon islikely origin is the CMP. It will be important to test
known as hybrid resistance or hematopoeitic histocom-whether this is true also in the allogeneic setting, and
patibility (Hh) resistance and is not completely under-whether dendritic cells of either CMP or CLP origin or
stood but is thought to occur because hematopoieticCD81 or CD82 phenotype can be involved in the induc-
cells express unique antigens that are recognized bytion and maintenance of transplantation tolerance (see
radioresistant natural killer (NK) and T cells (Yu et al.,below). It is of interest that the CD81 DC has a phenotype
1992). The experimental evidence for the role of NK cellsindistinguishable from either veto cells or non-T cells
in resistance to engraftment of MHC-disparate HSC isfound in the bone marrow that facilitate the engraftment
supported by studies using antibody reagents to targetof cotransplanted allogeneic HSC (Gandy et al., 1999).
NK cells in lethally irradiated recipients. KTLS HSC are
readily accepted in mice that are conditioned in thisTransplantation of Allogeneic HSC
manner as compared to preparation with radiation alone
Transplantation of allogeneic hematopoietic cells is rou-
(Shizuru et al., 1996). Dramatic reduction in the barrier
tinely performed in clinical practice for the treatment
is observed since HSC engraft even across the most
of hematologic malignancies and bone marrow failure
resistant MHC-disparate strain combinations.
states. Currently, most hematopoietic grafts are a com- The radioresistant immune barrier can also be
posite of HSC, multipotent progenitors, and differenti- breached by transplantation of escalated doses of HSC.
ated cells, including mature immune cells. Because only For example, in a defined donor-host combination, such
HSC can self-renew and give rise to all blood lineages, as C57BL/Ka to BALB/c, the minimum dose of HSC to
HSC are the only cells necessary to engraft and maintain save 95% of the irradiated hosts is 1000 KTLS cells, 10-
life-long hematopoiesis following allogeneic hematopoi- fold the number required for congenic radioprotection
etic cell transplantation (HCT). However, the therapeutic (Uchida et al., 1998). Such hosts engraft .500 WBC/
benefit of allogeneic HCT is to not only provide recipi- ml and .200,000/ml platelets by days 22–25 after HSC
ents with a healthy source of HSC, but because the injection. However, 5000 HSC results in donor en-
grafts also contain T cells and other immune cell popula- graftment by 14 to 16 days, and 10,000 HSC results in
tions, a phenomenon known as graft versus tumor (GVT) 10–11 day engraftment times (Uchida et al., 1998). This
has been observed against a number of malignancies latter dose is only 2-fold higher than the dose required
(Antin, 1993; Truitt et al., 1996). Immune cell populations for rapid engraftment in CD45 congenic hosts. The abil-
in the graft also function to enhance or facilitate en- ity of higher doses of HSC to engraft suggests that an
graftment of HSC (Gandy et al., 1999). Unfortunately, element of host competition for stem cell niches is an
these passenger immune cells also contribute negative important aspect of resistance to engraftment, or alter-
aspects. A major complication of allogeneic HCT is the natively that facilitating elements (see below) arise from
problem of graft versus host disease wherein an immune donor HSC in a time frame sufficient to ameliorate the
response is elicited against normal host tissues (Ferrara rejection mechanisms.
et al., 1999). GVHD is a significant cause of morbidity Engraftment of purified allogeneic HSC can be facili-
and mortality following allogeneic HCT, and to prevent tated by the cotransfer of non-HSC populations (Martin,
GVHD all patients undergo prolonged immunosuppres- 1990; Kaufman et al., 1994; Gandy et al., 1999). The
sive treatment. Transplantation of purified HSC will elim- finding that immune cells contained within unmanipu-
inate the problem of GVHD; however, elimination of im- lated bone marrow can enhance engraftment was ini-
tially based on clinical experiences. Following the deter-mune cells from the hematopoietic grafts can potentially
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mination that T cells are the primary mediators of GVHD, yet eliminate the possibility of GVHD. HSC transplanta-
tion performed in mice across MHC barriers reveals thatstrategies to purge BM grafts of T cells were applied to
these hosts are tolerant to heart, islet, or other tissueclinical protocols. Unfortunately, an increased number
transplants from the stem cell donor strain or the irradi-of such allogeneic bone marrow transplants failed to
ated host strain (Gandy and Weissman, 1998; Shizuruengraft, resulting in significantly increased deaths from
et al., 2000). While these hosts can reject third partythis complication (Verdonck et al., 1994). Identification
tissue transplants and make humoral antibody re-of the facilitating population by phenotype has been
sponses, their immune responses to minor (mHC) anti-performed most extensively in murine bone marrow-
gens and probably to infectious agents is subnormalderived populations transplanted across MHC barriers.
(Shizuru et al., 2000). Surprisingly, many of the T cell-The population is CD81 and both TCR1CD8a1 and
mediated MHC rejection responses in these chimerasTCR2CD8a1 subpopulations demonstrate facilitative
are restricted to donor HSC MHC allelic determinantspotential (Gandy et al., 1999). Further analysis of the
(Shizuru et al., 2000), suggesting that HSC grafts canTCR2 fraction reveals it to be CD81TCR2CD32CD11c1
give rise to positive selective elements, a finding not inand thus it is a non-T cell population. Even relatively
keeping with the original proposal that thymic epitheliumlow doses of the CD81 bone marrow-derived population
MHC alleles determine T cell MHC restriction. Allogeneicdemonstrate significant facilitating capacity—doses
HSC grafts also mediate central and peripheral deletionthat do not cause evidence of overt GVHD. Facilitating
of T cell subsets as shown by measuring informative Vbcells appear to function by elimination of residual radio-
T cell families that differed between donor and hostresistant host T cell and other immune cell populations
strains (Shizuru et al., 2000). Antigen-presenting den-(Shizuru et al., 1996; Gandy et al., 1999). Expression of
dritic cells (DC) are derived from HSC (and in fact DCCD8 was shown to be essential for facilitating function,
of both the CD81 and CD82 phenotype are derived fromsince transplantation of bone marrow from CD8a2/2
CMP or CLP) (Traver et al., 2000). Thus, it is possiblemice demonstrates markedly reduced engraftment ca-
that these populations mediate the selective actions ofpability as compared to wild-type bone marrow (Gandy
the HSC grafts. Similar effects on host immune re-et al., 1999). The exact role of CD8 in facilitation is not
sponses can be observed when nonmyeloablative regi-yet known and warrants further study.
mens are used to prepare mice for transplantation ofThe importance of the GVT effect as a therapeutic
HSC. Under those circumstances, mice are partial chi-benefit following allogeneic HCT for hematologic malig-
meras in all white blood cell lineages yet demonstratenancies has been widely described (Antin, 1993; Truitt
tolerance to organ allografts and the grafts similarly me-et al., 1996). GVT is mediated by mature lymphoid cells;
diate negative T cell selection (J. Shizuru, unpublishedthus, HSC that are immunologically naive are expected
data).to fail to confer this benefit. Indeed, in an in vivo model
Hematopoietic transplantation may be applied to theof tumor relapse following HCT it was demonstrated
treatment of autoimmune diseases (Ikehara et al., 1985).that purified HSC grafts were devoid of GVT activity
Many (if not all) conditions of T cell autoimmunity are(Ito and Shizuru, 1999). However, GVT activity can be
determined by particular MHC alleles. In the case ofrecovered by cotransfer of non-HSC populations. CD81
type 1 diabetes in mouse and human, a known singleBM cells cotransferred with HSC can confer measurable
amino acid mutation in part of the MHC class II moleculeGVT, and at low doses CD81 cells cause no overt GVHD
at or near the TCR binding sites leads to the emergence(Ito and Shizuru, 1999). The development of approaches
and persistence of autoimmune T cells capable ofto identify GVT conferring populations that do not induce
mounting a destructive immune response to pancreaticGVHD is an area of active investigation by researchers
b cells, as well as against a number of epithelial tissuesworldwide (Antin, 1993; Truitt et al., 1996). While it is not
(Todd et al., 1988). Without understanding the mecha-possible to utilize grafts containing HSC only to confer
nisms by which hosts homozygous for particular mutant
maximal GVT activity, the technologies are now avail-
alleles permit autoimmune T cells to emerge and persist,
able to attempt transplantation of HSC plus candidate
it is clear that at least some thymic and peripheral auto-
GVT conferring cells. immune T cell negative selection occurs through the
action of antigen-presenting DC. It is therefore reason-
Allogeneic HSC Transplantation to Alter Responses able to propose that HSC from donors not possessing
against Alloantigens and Autoantigens these autoimmune susceptibility MHC-II alleles might,
The clinical applications of HSC transplantation that do upon transplantation, abrogate the process of autoim-
not require adjunctive cell populations are in the alter- mune T cell development and/or survival. In fact, trans-
ation of host immune responses to alloantigens and plantation of AKR (H2Kk) HSC into lethally or sublethally
autoantigens. The classic studies from the 1950s by irradiated NOD mice results in the abrogation of autoim-
Billingham et al. (1953) demonstrated that hematolym- munity, whether donor cells replace host cells following
phoid grafts can induce tolerance to alloantigens. Al- myeloablative preparation or if the two populations re-
though this approach has remained of great interest to side in coexistence following nonmyeloablative treat-
the transplant community, it has not been reduced to ment (J. Shizuru, unpublished data). If the mice had
clinical practice because of the morbidity and mortality insulitis but not diabetes at the time of HSC transplanta-
associated with the allogeneic HCT procedure, espe- tion, then sufficient islet function or regeneration occurs
cially the up-front morbidity associated with myeloabla- and the disease pathogenesis was blocked so that the
tive regimens and the possibility of life-threatening mice never developed hyperglycemia. For mice that are
GVHD. Transplantation of allogeneic KTLS HSC has already hyperglycemic (as is the case for humans with
insulin-dependent diabetes mellitus), although the HSCbeen proven to profoundly alter host immune responses
Immunity
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transplantation can block the autoimmune response, markers to define clonal self-renewing (Spangrude et
al., 1988; Morrison and Weissman, 1994) or oligopotentself-regeneration of islets does not occur, at least in
rare subpopulations (Kondo et al., 1997; Akashi et al.,time to reverse the potentially lethal consequences of
2000). This strategy was used successfully to isolatediabetes. In preliminary experiments, cotransplantation
neural crest stem cells using antibodies against the cellof AKR HSC and AKR islets into diabetic NOD mice
surface antigen p75, the low-affinity neurotrophin recep-leads to a cure of the diabetes with no evidence of
tor, and P0, a peripheral myelin protein (Morrison et al.,residual autoimmunity (J. Shizuru, unpublished data)
1999). For mouse central nervous system stem cellsThe cure of hyperglycemia in NOD mice with a simulta-
(CNS-SC), Johansson and Frisen isolated mouse epen-neous HSC and islet transplantation is model for other
dymal cells that have NSC characteristics by selectingautoimmune diseases that will likely require not only
cells with Notch antiserum from adult brain (Johanssonblockade of the immune response but the replacement
et al., 1999). Doestch and Alvarez-Buylla showed thatof the tissues destroyed by the pathogenic process.
cells in the subventricular zone that express the cyto-These other diseases include certain types of T cell
plasmic astrocyte marker GFAP are likely to be the cellsdemyelinating states in mice and multiple sclerosis in
within the neurogenic site that give rise to CNS multilin-human, destructive rheumatoid arthritis, and perhaps in
eage differentiation (Doetsch et al., 1999). We have di-diseases such as MHC linked narcolepsy, wherein a
rectly isolated human clonogenic neurosphere initiatingparticular population of neurons secreting arrexin/hypo-
cells that are CNS-SC using antibodies to cell surfacecretin are lost. In each of these cases, we propose that
markers; they are phenotypically CD1331, 5E121,cotransplantation of HSC and the appropriate tissue-
CD342, CD452, and CD242/lo (Uchida et al., 2000). Singlespecific stem cells into nonmyeloablated but lymph-
CD1331CD342CD452 sorted cells initiated neurosphereoablated hosts will be required for abrogation of autoim-
cultures and the progeny of clonogenic cells could dif-munity and regeneration of normal function.
ferentiate into both neurons and glia. Single cells re-
isolated from sorted/expanded CD1331CD342CD452Neural Stem Cells
(CD1331) cells also initiated neurosphere cultures whenLike hematopoiesis, neurogenesis proceeds from clono-
replated as single cells and were able to reestablishgenic neural stem cells (NSC) with self-renewal and
neurosphere cultures, demonstrating the self-renewalmultilineage differentiation properties (Gage, 2000). NSC
potential of this highly enriched population. CD1332are able to give rise to different classes of neurons,
CD342CD452 sorted cells, which represent 95% of fetalastrocytes, and oligodendrocytes, and therefore have
brain cells, fail to initiate neurospheres. Upon trans-the potential to replace or repair cells lost in neurode-
plantation into brains of NOD-SCID immunodeficientgenerative diseases, such as Parkinson’s disease and
neonatal mice, the sorted/expanded CD1331 neuro-Alzheimer’s disease, or damaged nervous systems,
sphere cells engraft for at least 7 months. Some of thesuch as ministrokes and spinal cord injury. Initially, the
grafted human cells continue to proliferate in the neuro-platform for enrichment and purification of neural stem
geneic sites (i.e., subventricular zone of the lateral ventri-and progenitor cells was achieved by defining culture
cle and the dentate gyrus of the hippocampus) where
conditions that allowed propagation of rodent neural
endogenous mouse neural stem/progenitor cells also
cells containing precursors for neurons, astrocytes, and
proliferate. The progeny of human cells migrate and
oligodendrocytes (Ray et al., 1993; McKay, 1997). In an
differentiate into neurons in the olfactory bulb as well
another approach, rodent central nervous system (CNS) as in the dentate gyrus of the hippocampus (Figure 3).
subpopulations could be immortalized by transfected Thus, these sorted/expanded non-genetically modified
v-myc, allowing them to expand in vitro (Snyder, 1994). human CNS-SC show potent engraftment, proliferation,
CNS stem/progenitor cells can grow in either mono- migration, and neural differentiation in a site-specific
layers on substrate-coated tissue culture plates (Ray et manner without any evidence of tumorigenicity.
al., 1993; McKay, 1997) or as self-adherent complexes These human CNS-SC-derived neurosphere culture
of cell, forming clusters known as neurospheres (Reyn- cells give extensive and life-long engraftment, self-
olds et al., 1992; Weiss et al., 1996). These long-term renewal, migration, and multilineage differentiation in
cultured populations can self-renew and maintain the the mouse brains they inhabit. Their widespread infiltra-
multilineage differentiation capacity to produce neu- tion, neuronal differentiation, and dendrite extension in
rons, astrocytes, and oligodendrocytes (Weiss et al., the NOD-SCID neonatal transplantation model raise the
1996). In vivo analysis of transplanted cultured popula- possibility that they would engraft similarly in human
tions containing rodent CNS stem and progenitor cells hosts. Since none of these human neurosphere cells are
show engraftment, migration, and site-specific multilin- histocompatible with their human hosts, it is likely that
eage differentiation in mice and rats (Lois and Alvarez- despite the reported immune privilege of intracranial
Buylla, 1994; Suhonen et al., 1996). Non-genetically transplants, the host will be treated with the usual trans-
modified long-term neurosphere cultures that likely con- plant immunosupression regimen. The minimal immuno-
tain human CNS stem/progenitor cells can be continu- suppression regimen, which can be guided by alloge-
ously propagated in vitro (Carpenter et al., 1999); these neic CNS cell preclinical transplant models, will likely
show similar engraftment, migration, and site-specific be evaluated empirically in human clinical trials. In hu-
differentiation upon transplantation into immunosup- man CNS neurodegenerative disorders, there are four
pressed rats (Fricker et al., 1999). distinct settings for therapeutic CNS-SC or neural cell
As described above, hematopoietic stem and different transplants. (1) The injected cells bring needed products
classes of progenitor cells have been identified by em- in the vicinity of the disease process, and the differentia-
tion of the product within that vicinity is sufficient toploying monoclonal antibodies (mAb) to cell surface
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Figure 3. Detection of Human Neurons in the Dentate Gyrus of a NOD/SCID Mouse
The sagittal section of the transplanted mouse brain was stained with monoclonal antibodies specific to human neural cells (green) and
counterstained with Hoechst (S. Tamaki and N. U., unpublished data).
alleviate the pathogenic process. Likely examples of reason for optimism in the latter settings. However, the
recent knowledge that the brain undergoes life-longthis setting are the set of lysosomal storage disorders
(Niemann-Pick, Tay-Sachs, etc.) that have CNS conse- neurogenesis with formation of precise synaptic net-
works (Gage, 2000) is of great interest for cell-basedquences and Parkinson’s disease. (2) The injected cells
must integrate more precisely into the CNS, forming or therapy. Research in the near future should be informa-
tive as to the use of transplantation in these other set-reforming an extensive and appropriate synaptic net-
work. Neurodegenerative diseases with profound men- tings.
tal changes such as Alzheimer’s disease are likely exam-
ples. (3) The transplanted cell can either protect against Liver Stem Cells and HSC-Derived Hepatocytes:
Potential for Cell Therapy of Human Liver Diseasesneural cell death by providing needed glial elements, as
in ministrokes or are cells that can actively suppress Treatment for advanced liver disease generally remains
supportive. Currently, liver transplantation is the onlyspontaneously firing cell clusters, as in temporal lobe
epilepsy. Included in this category would be remyelina- available therapy for end-stage liver failure. However,
many of these patients die each year waiting for suitabletion by oligodendrocytes in toxic or immune-based de-
myelination. For example, in multiple sclerosis if the donor organs. Liver transplants are limited by the num-
ber of qualified and compatible donors. In addition, dueautoimmune disease is ablated (see above). (4) The
transplanted cells can prevent the development of to the recent increase in the incidence of hepatitis C,
now the leading indication for liver transplant, the de-pathogenic structures, such as the intraspinal cord cysts
(following crush injury) that enlarge over days to com- mand for orthotopic liver transplantion has increased
dramatically .press the long spinal motor and sensory tracts. There
is reasonable evidence to be optimistic that CNS-SC Finding an alternative method for liver transplantation
is essential, and a cell-based therapy for liver regenera-transplants will be effective in the first category and less
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Figure 4. An Illustration of HSC Plasticity
HSC can give rise to both mature cells of the blood cells and differentiated hepatocytes of the liver.
tion is a promising new approach capable of providing tion. In these models, 2/3 of the liver mass is removed.
Interestingly, less than a week after the operation, thetreatment for thousands of patients, as the cells might be
available from living donors. In the recent years, cellular remaining lobes enlarge to replace the lost hepatic tis-
sues. These studies established that the regenerativetherapy has been successfully applied in rodent models
using primary hepatocytes, the chief functional cells of process was almost certainly the result of the prolifera-
tion of mature hepatocytes. It is not known, however,the liver. Clinical studies suggest that hepatocyte trans-
plantation may be useful for bridging patients to whole whether stem cells and their progeny participate also
in this regenerative process, and if so, if they are theorgan transplantation, for providing metabolic support
during liver failure, and for replacing whole organ trans- only source of sustainable regeneration. Liver stem cells
have been elusive and are waiting to be identified. Evenplantation in certain metabolic liver diseases (Strom et
al., 1999). However, again the shortage of donor organs the concept of liver stem cells in the adult liver has been
controversial for many years. It is now accepted thatand allograft rejection limits the available livers for hepa-
tocyte transplantation. The potential of this technique under certain conditions where mature hepatocytes
cannot regenerate, stem cells and progenitor cells, per-is also challenged by hepatocyte viability after isolation
and the poor cryopreservation of these cells for later use. haps oval cells, will proliferate and eventually differenti-
ate into hepatocytes in the adult liver (review by Bis-With the study of regeneration of the hematopoietic
system and the discovery of HSC as the only source gaard and Thorgeirsson, 1996). Several laboratories
have recently found that within the liver reside clono-of cells required for both short-term engraftment and
sustained regeneration of the blood system, it became genic precursors of both hepatocyte and bile duct
progeny. It shall be important to determine if they areimportant to know whether liver stem cells or their prog-
eny would be a better alternative for liver regeneration. clonogenic cells that undergo both self-renewal and dif-
ferentiation.Liver regeneration after the loss of hepatocytes is a
fundamental mechanism in response to injury (review
by Michalopoulos and DeFrances, 1997). It likely evolved Turning Blood into Liver
One can argue that it has been so difficult to find liverfrom the catastrophic result of liver loss caused by food
toxins. A simple experimental model of partial hepatec- stem cells in an adult liver because the ultimate precur-
sor of liver stem cells may reside in another tissue. Re-tomy was developed in the rat to study liver regenera-
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Figure 5. Model for Stem Cell Differentiation
The totipotent stem cell gives rise to the pluripotent embryonic stem cells (ES cells), which give rise to both the germline and perhaps putative
somatic stem cells. The somatic stem cells are multipotent stem cells, and tissue-restricted stem cells may derive from multipotent stem
cells. Hematopoietic stem cells (HSC), muscle stem cells (Muscle-SC), and neural stem cells (CNS-SC) may be multipotent stem cells or
tissue-restricted stem cells that dedifferentiate into multipotent stem cells. Only prospectively isolated HSC have been shown to give rise to
both blood and liver (hepatocytes).
cent publications have suggested that adult bone mar- HSC were able to generate mature hepatocytes in the
liver of the tyrosinemic mouse. With a homing efficiencyrow is a potential source of oval cells (Petersen et al.,
1999) and hepatocytes (Alison et al., 2000; Theise et al., of 5%–10% for the bone marrow environment, only 5
HSC were able to engraft in the bone marrow, reconsti-2000, 2000a). These reports did not establish the nature
of the progenitor cell(s) or whether they can reconstitute tute the hematopoietic system, and eventually differenti-
ate into hepatocytes (Figure 4). This property resided inliver function. Bone marrow is composed of a mixed
population of cells of different origins. There are at least bone marrow in the Lin2 but not Lin1 population; the
ckit1 but not the ckit2 population; and in the Sca-11two types of stem cells residing in the bone marrow,
HSC, as described above, and the mesenchymal stem population much greater than in the Sca-12 population.
Thus, the effective population in BM is at least KLS. Thiscells that can differentiate in a variety of cell types like
chondrocytes, osteocytes, and adipocytes. In addition, allowed us to transplant BM cells into lethally irradiated
tyrosinemic mice. After hematopoietic engraftment, theit has been claimed that bone marrow contains precur-
sors of endothelium, skeletal muscle, and brain, to name animals were selected for liver engraftment. Several
months after transplantation, the animals were clinicallya few end organs and tissues (Pereira et al., 1995; Ferrari
et al., 1998; Kopen et al., 1999). Those previous studies healthy with restored biochemical functions and sub-
stantial engraftment of hepatocytes in their liver. Thisdid not distinguish whether HSC, mesenchymal stem
cells, or as-yet-unknown progenitors residing in the extraordinary potential of HSC to generate hepatocytes
may have considerable advantages over the use of he-bone marrow were responsible for liver engraftment.
Using an inducible animal model of a lethal hereditary patocytes alone for liver regeneration. Bone marrow or
MPB can be easily obtained and allows the use of living,liver disease (Grompe et al., 1995), tyrosinemia type 1,
two important points were made: the identification of related, HLA matched donors. However, with current
protocols in mice, the HSC to hepatocyte transitionan adult stem cell that could give rise to hepatocyte
differentiation, and the therapeutic potential these cells takes weeks to months. Therefore identification and en-
richment of liver stem and progenitor cells is still a proxi-might have for liver diseases (Lagasse et al., 2000). First,
rigorously purified LT-HSC from adult bone marrow were mal goal, especially if in vitro expansion methods be-
come available. Cotransplantation of hepatocytes orinjected intravenously into lethally irradiated type 1 tyro-
sinemic mice at limiting doses. HSC gave rise to donor- liver stem and progenitors along with donor HSC should
allow both the induction of transplant tolerance withoutderived hematopoietic and hepatic cells. As few as 50
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lifelong immunosuppression and provide a source of plasticity of freshly isolated neural stem cells. It is con-
ceivable that neural stem cells acquired their multipotentHSC for long-term hepatocyte development. It will also
be important to identify the mechanisms by which potential through in vitro culture.
So with many tissue-specific stem cells giving rise toHSC ! liver differentiation occurs, so that future trans-
plants may only require HSC. developmentally unrelated lineage-specific cells (Figure
5), we might have to rethink the notion of germ layer
origins of some of the tissues. Blood and liver are cur-HSC, a Multipotent Stem Cell
rently believed (and taught) to be derived from two dis-It seems like bone marrow is the source of many sur-
tinct germ layers, mesoderm and endoderm, respec-prises (Figure 5). Transplanted bone marrow cells are
tively. Yet the only direct, clonal precursor shown toobserved to give rise to hepatocytes, muscle (Ferrari
give rise to hepatocytes in an adult regeneration modelet al., 1998), astrocytes (Kopen et al., 1999), neurons
is HSC. Can we exclude an HSC origin of liver during(Brazelton et al., 2000; Mezey et al., 2000), or primitive
embryogenesis, perhaps dependent on endodermalmesenchymal cells (Pereira et al., 1995). Subsequent
buds for their transdifferentiation? And do we have tostudies have shown that an enriched bone marrow (BM)
redefine the notion of tissue-specific stem cells? Wepopulation that contains HSC based on Hoechst dye
need to identify each tissue-specific stem cell and at theexclusion (side population) can differentiate to muscle
clonal level determine the full developmental potential of(Gussoni et al., 1999). The biological significance of
these cells. But even if the extraordinary plasticity ofthese data could be interpreted by the possibility that
tissue stem cells does not reflect the in vivo potentialsome tissue-specific stem cells, perhaps mislabeled as
these cells exercise during normal development, it willHSC, are multipotent stem cells possessing a broader
still be scientifically important to study and understandrange of differentiation potential. Alternatively, tissue-
this phenomenon, and, of course clinically it might ex-specific stem cells may be more plastic than thought
pand the potential for new cell-based therapies.and are able to dedifferentiate or be reprogrammed de-
pending on the environment. However, because many
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